Your browser doesn't support javascript.
loading
A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system.
Manley, Peter E; Trippett, Tanya; Smith, Amy A; Macy, Margaret E; Leary, Sarah E S; Boklan, Jessica; Cohen, Kenneth J; Goldman, Stewart; Kilburn, Lindsay B; Dhall, Girish; Devin, Jeanne; Herzog, Cynthia E; Partap, Sonia; Fauchet, Floris; Badreddine, Emmy; Bernard, John P; Chi, Susan N.
Afiliação
  • Manley PE; Department of Pediatric Hematology/Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Trippett T; Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York City, New York.
  • Smith AA; Department of Pediatric Hematology-Oncology, Arnold Palmer Hospital, Orlando, Florida.
  • Macy ME; Department of Pediatric Hematology, Oncology & Bone Marrow Transplantation, Children's Hospital Colorado, Aurora, Colorado.
  • Leary SES; Department of Hematology/Oncology, Seattle Children's Hospital, Seattle, Washington.
  • Boklan J; Department of Hematology/Oncology, Phoenix Children's Hospital, Phoenix, Arizona.
  • Cohen KJ; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
  • Goldman S; Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
  • Kilburn LB; Center for Cancer and Blood Disorders, Children's National Medical Center, Washington, District of Columbia.
  • Dhall G; Department of Pediatric Neuro-Oncology, Children's Hospital Los Angeles, Los Angeles, California.
  • Devin J; Sanofi Genzyme, Cambridge, Massachusetts.
  • Herzog CE; Department of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Partap S; Department of Pediatric Neurology, Lucile Packard Children's Hospital at Stanford, Palo Alto, California.
  • Fauchet F; Sanofi Genzyme, Cambridge, Massachusetts.
  • Badreddine E; Sanofi Genzyme, Cambridge, Massachusetts.
  • Bernard JP; Sanofi Genzyme, Cambridge, Massachusetts.
  • Chi SN; Department of Pediatric Hematology/Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Pediatr Blood Cancer ; 65(9): e27217, 2018 09.
Article em En | MEDLINE | ID: mdl-29750396
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Taxoides / Neoplasias / Antineoplásicos Fitogênicos Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies Limite: Adolescent / Child / Child, preschool / Female / Humans / Male Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Taxoides / Neoplasias / Antineoplásicos Fitogênicos Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies Limite: Adolescent / Child / Child, preschool / Female / Humans / Male Idioma: En Ano de publicação: 2018 Tipo de documento: Article